Physician profile
James W Jackson
NPI 1467547836
$1,499.64
in general payments reported to CMS, 2019-2025
19 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $132 · 2021: $266 · 2022: $228 · 2023: $214 · 2024: $294 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.88 |
| Education | $168.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $370.84 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $195.18 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $151.69 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $137.93 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $127.66 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $116.67 | 2021-2024 | |
| Amgen INC. | $71.69 | 2021 | |
| Vifor Pharma, INC. | $59.36 | 2020-2022 | |
| Daiichi Sankyo INC. | $49.69 | 2019-2023 | Injectafer |
| Horizon Therapeutics Plc | $36.56 | 2022 | |
| Mallinckrodt Hospital Products INC. | $32.22 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $27.60 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $26.42 | 2021 | |
| Cvrx, INC. | $21.01 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $18.43 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.42 | 2025 | Shingrix |
| Xeris Pharmaceuticals, INC. | $15.69 | 2024 | Keveyis |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Akebia Therapeutics INC | $9.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.